This site is intended for health professionals only
  • PulseToday|
  • Pulse Learning|
  • Practical Commissioning|
  • Pulse Seminars|
  • Pulse Jobs|
Pulse
Login Sign up here if you don't have a login
Forgotten password? Caps Lock is on.
Thursday 23 February 2012
Facebook Twiter Linkedin
  • Home
  • News
  • Comment
  • Clinical
  • Practice Business
  • Commissioning
  • Forum
  • Events
  • Jobs & Careers
  • Help & Support
  • About Pulse
  • Awards 2011
  • A right to refer
    • Submit your stories
  • Health bill
    • Latest news on the health bill
  • Copperfield
  • Useful resources
    • Clinical resources
    • Practice business resources
    • Commissioning resources
  • This week's issue
  • Practical Commissioning
    • News
    • Blogs
    • CPD
    • Focus on...
    • Case studies
    • Opinion
    • Policy updates
    • Diaries
    • Evidence based commissioning
    • All you need to know
  • Sponsored information
    • Money Matters
    • Managing over active bladder by Orion Pharma
    • Managing type 2 diabetes by Takeda
    • Asthma Issues by Teva UK Ltd
    • Information from Flora pro.activ
    • Managing pain by Goldshield
    • Managing UTI by Goldshield
    • Managing COPD by Boehringer Ingelheim Ltd and Pfizer Ltd
    • Circadin®▼ (prolonged release melatonin) by Lundbeck Ltd
    • Spotlight Savings by Teva UK Ltd
    • Contraceptive choices for women with CV risk factors
    • Heart Zone by Takeda UK Ltd.
  • Videos

SPONSORED INFORMATION

Circadin ®▼ - Information from Lundbeck Ltd.

Circadin ® (prolonged release melatonin) licence extended to include treatment for up to 13 weeks¹ in patients with primary insomnia.

Dialogue with elderly patients

Prescribing information

The role of melatonin in sleep

The role of prolonged-release melatonin in the management of primary insomnia
  • Contact us
  • Pulse seminars
  • Pulse Medical Store
  • Terms and Conditions
  • Privacy Policy
  • Site map